Kenacort-A

KENACORT-A^®
CREAM / OINTMENT
(triamcinolone acetonide)


DESCRIPTION
Kenacort-A Cream (Triamcinolone acetonide cream 0.1 %) provides Triamcinolone acetonide 1 mg per gram in a vanishing cream base.
Kenacort-A Ointment (Triamcinolone acetonide ointment 0.1 %) provides Triamcinolone acetonide 1 mg per gram in Plastibase® (Plasticized Hydrocarbon Gel), a polyethylane and mineral oil gel base.

ACTION
Kenacort-A Cream and Ointment are primarily effective because of their anti-inflammatory, antipruritic and vasoconstrictive actions.

INDICATIONS
Kenacort-A Cream and Ointment are Indicated for relief of the inflammatory manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS
Topical steroids are contraindicated in viral diseases of the skin, such as vaccinia and varicella, and in those patients with a history of hypersensitivity to any of the components of the preparations.
These preparations are not for ophthalmic use. Topical steroids should not be used when circulation is markedly impaired.

WARNINGS
Usage in Pregnancy
Although topical steroids have not been reported to have an adverse effect on the fetus, the safety of topical steroid preparations during pregnancy has not been absolutely established; therefore, they should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

PRECAUTIONS
If irritation develops, the product should be discontinued and appropriate therapy instituted.
In the presence of an infection, the use of appropriate antifungal or antibacterial agents should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
If extensive areas are treated or if the occlusive technique is used, the possibility exists of increased systemic absorption of the corticosteroid and suitable precautions should be taken.

ADVERSE REACTIONS
The following local adverse reactions have been reported with topical corticosteroids either with or without occlusive dressing: burning sensations, itching, irritation, dryness, folliculitis, secondary infection, skin atrophy, striae, miliaria, hypertrichosis acneform eruptions, maceration of the skin, and hypopigmentation. Contact sensitivity to a particular dressing material or adhesive may occur occasionally.

DOSAGE AND ADMINISTRATION
Apply a thin film to the affected area two to three times daily.

Occlusive Dressing Technique
Kenacort-A Cream:
Gently rub a small amount of the preparation into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion and cover with a pliable nonporous film. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the plastic film is applied or by briefly soaking the affected area in water. The frequency of changing dressing is best determined on an individual basis. Reapplication of the preparation is essential at each dressing change.
Kenacort-A Ointment :
Apply a thin coat of the ointment to the affected area and cover with a pliable nonporous film. If desired, the lesion may be moistened with a dampened clean cotton cloth before the plastic film is applied. The frequency of changing dressings is best determined on an individual basis.
Reapplication of the preparation is essential at each dressing change.

HOW SUPPLIED
Kenacort-A Cream and Ointment is available in tube of 10 gram.

STORAGE
Store below 30°C.

HARUS DENGAN RESEP DOKTER

Reg. No.	Kenacort-A Cream 10 g	D7812442 (Indonesia) R1004A3893 (Myanmar)
	Kenacort- A Ointment 10 g	D7812441 (Indonesia) 0504A3851 (Myanmar)

Manufactured by
PT Bristol-Myers Squibb Indonesia Tbk
Bogor-Indonesia
Under authority of
Bristol-Myers Squibb, Co.
Princeton, New Jersey, U.S.A.

Share this :